TABLE 2.
Virologic response
| Response categoryd | Value (no. [%]) by faldaprevir treatment duration |
Adjusted difference (95% CI) | |
|---|---|---|---|
| 12 wka (n = 81) | 24 wkb (n = 78) | ||
| W28VR | 61 (75.3) | 60 (76.9) | −1.25 (−14.3, 11.8) |
| RVR | 48 (59.3) | 56 (71.8) | 9.02 (−5.3, 23.3) |
| SVR12 | 56 (69.1) | 59 (75.6) | 3.41 (−10.1, 16.9) |
| SVR24c | 54 (66.7) | 58 (74.4) | 4.78 (−9.0, 18.6) |
a
Includes one patient with NS3/NS4 GT-6e (achieved SVR12 and SVR24).
b
One patient was noncompliant and lost to follow-up and was excluded from efficacy analysis.
c
Referred to as SVR in the text and other tables and figures.
d
W28VR, week 28 virologic response (HCV RNA was undetectable at week 28); RVR, rapid virologic response (HCV RNA was undetectable at week 4); SVR12, sustained virologic response, week 12 (HCV RNA was undetectable at posttreatment week 12); SVR24, sustained virologic response, week 24 (HCV RNA was undetectable at posttreatment week 24).